AdaptHealth Q4 revenue beats expectations, loss bigger than expected

Reuters
3 hours ago
AdaptHealth Q4 revenue beats expectations, loss bigger than expected

Overview

  • Healthcare-at-home provider's Q4 revenue beat analyst expectations

  • Q4 operating loss and pretax loss wider than analyst expectations

  • Company expanded footprint by acquiring HME provider in Hawaii

Outlook

  • AdaptHealth forecasts 2026 net revenue between $3.44 bln and $3.51 bln

  • Company expects 2026 adjusted EBITDA of $680 mln to $730 mln

  • AdaptHealth projects 2026 free cash flow of $175 mln to $225 mln

Result Drivers

  • PATIENT GROWTH - AdaptHealth set new patient census records in Sleep Health, Respiratory Health, and Wellness at Home

  • GEOGRAPHIC EXPANSION - Acquired a leading HME provider in Hawaii, expanding the company's footprint to its 48th state

  • DIGITAL ENGAGEMENT - More than doubled myApp users to 327,300, enhancing digital patient engagement

Company press release: ID:nBw8nk0Wma

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Revenue

Beat

$846.29 mln

$831.61 mln (8 Analysts)

Q4 Net Income

-$101.54 mln

Q4 Operating Income

Miss

-$73.28 mln

$89.60 mln (8 Analysts)

Q4 Pretax Profit

Miss

-$97.99 mln

$65.06 mln (7 Analysts)

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for Adapthealth Corp is $13.00, about 26.3% above its February 23 closing price of $10.29

  • The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 8 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10